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Risk of cardiometabolic (CM) disease is characterised by elevated visceral adipose tissue (VAT) and a number of associated biomar-
kers(1). Some dietary carbohydrates (CHO) have been found to contribute to VAT accumulation(2). Little is known about the impact
of following a low-carbohydrate diet versus a high-carbohydrate diet on VAT, adiponectin (ADPN), leptin (LEPT) and leptin:adipo-
nectin ratio (LAR). The aim of this investigation was to assess the impact of dietary carbohydrates (CHO) on VAT and emerging CM
risk markers in a sample of 10 healthy normal-weight and overweight Caucasian adults aged 32–60 (80 % male) at increased CM
risk(3). This pilot study received ethical approval from Liverpool John Moores University Research Ethics Committee (16/ELS/
029) and was registered with ClinicalTrials.gov (Ref. NCT03257085).
Participants were randomly allocated to one of two groups and asked to either consume <50 g/d of dietary CHO (low-carb (LC)) or
to follow the UK dietary guidelines and obtain >50 % energy from CHO (high-carb (HC)) for a duration of 8 weeks. VAT was ana-
lysed via bioelectrical impedance (SECA mBCA 515). Blood plasma samples were collected at baseline (BL), interim point (IP) and
endpoint (EP) after a 12-hour overnight fast, immediately processed and frozen at -80°C. Thawed plasma samples were analysed via
immunoassay technology (Randox Evidence Investigator™ Metabolic Syndrome Arrays I and II) for ADPN and LEPT levels.
Statistical analysis was undertaken using IBM SPSS 24®.
Parametric data was analysed via two-way mixed ANOVA; non-parametric data was analysed via Mann-Whitney U test and
Friedman test. Average daily carbohydrate intake in the LC group was 44·2 g at IP and 48·9 g at EP.
There were no signiﬁcant differences between groups at any time point for ADPN, LEPT, LAR or VAT and no signiﬁcant inter-
actions for time or group*time for ADPN, LEPT or LAR. However, in the LC group VAT decreased signiﬁcantly between baseline
and endpoint by 15 % (p = ·015) Over the course of the intervention ADPN and LEPT decreased non- signiﬁcantly (by 4 % and 70 %
respectively) in the LC group, whilst increasing non-signiﬁcantly in the HC group (9 % and 65 % respectively). LAR increased in the
HC group throughout the study, whilst LAR in the LC group decreased albeit not signiﬁcantly.
VAT (litre) ADPN (ng/mL) LEPT (ng/mL) LAR
BL IP EP Median Median Median
M SD M SD M SD BL IP EP BL IP EP BL IP EP
LC 4·1a 1·2 3·8 1·3 3·5a 1·2 8·9 8·6 8·5 3·96 1·64 1·20 0·45 0·19 0·14
HC 2·7 0·1 1·6 0·3 2·5 0·1 11·3 13·4 12·3 0·97 1·1 1·60 0·07 0·07 0·46
ADPN= adiponectin, BL = baseline, EP = endpoint, HC = high-carbohydrate, moderate fat diet, IP = interim point, LAR = leptin:adiponectin ratio, LEPT = leptin, LC
= low-carbohydrate, high-fat diet, VAT = visceral adipose tissue, ap = ·015. NB: interquartile ranges not provided for median values due to missing data.
Higher LAR has been found to be a marker of increased CM risk(4). In conclusion, while the signiﬁcant reduction in VAT in the LC
group corresponds with the reduction of LAR further evidence is required to corroborate these ﬁndings. Previous evidence for LC is
supportive for improved CM health from various biomarkers(5); LAR should be considered as a useful endocrine addition for future
LC studies.
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